Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma

医学 内科学 不利影响 肝细胞癌 胃肠病学 肿瘤科 外科
作者
Bernhard Scheiner,Daniel Roessler,Samuel Phen,Mir Lim,Katharina Pomej,Tiziana Pressiani,Antonella Cammarota,Thorben Fründt,Johann von Felden,Kornelius Schulze,Vera Himmelsbach,Fabian Finkelmeier,Ansgar Deibel,Alexander Reinhard Siebenhüner,Kateryna Shmanko,Pompilia Radu,Birgit Schwacha-Eipper,Matthias P. Ebert,Andreas Teufel,Angela M. Djanani
出处
期刊:JHEP reports [Elsevier BV]
卷期号:5 (1): 100620-100620 被引量:68
标识
DOI:10.1016/j.jhepr.2022.100620
摘要

Background & Aims: We investigated the efficacy and safety of immune checkpoint inhibitor (ICI) rechallenge in patients with hepatocellular carcinoma (HCC) who received ICI-based therapies in a previous systemic line. Methods: In this international, retrospective multicenter study, patients with HCC who received at least two lines of ICI-based therapies (ICI-1, ICI-2) at 14 institutions were eligible. The main outcomes included best overall response and treatment-related adverse events. Results: Of 994 ICI-treated patients screened, a total of 58 patients (male, n = 41; 71%) with a mean age of 65.0±9.0 years were included. Median systemic treatment lines of ICI-1 and ICI-2 were 1 (range, 1-4) and 3 (range, 2-9), respectively. ICI-based therapies used at ICI-1 and ICI-2 included ICI alone (ICI-1, n = 26, 45%; ICI-2, n = 4, 7%), dual ICI regimens (n = 1, 2%; n = 12, 21%), or ICI combined with targeted therapies/anti-VEGF (n = 31, 53%; n = 42, 72%). Most patients discontinued ICI-1 due to progression (n = 52, 90%). Objective response rate was 22% at ICI-1 and 26% at ICI-2. Responses at ICI-2 were also seen in patients who had progressive disease as best overall response at ICI-1 (n = 11/21; 52%). Median time-to-progression at ICI-1 and ICI-2 was 5.4 (95% CI 3.0-7.7) months and 5.2 (95% CI 3.3-7.0) months, respectively. Treatment-related adverse events of grade 3-4 at ICI-1 and ICI-2 were observed in 9 (16%) and 10 (17%) patients, respectively. Conclusions: ICI rechallenge was safe and resulted in a treatment benefit in a meaningful proportion of patients with HCC. These data provide a rationale for investigating ICI-based regimens in patients who progressed on first-line immunotherapy in prospective trials. Impact and implications: Therapeutic sequencing after first-line immune checkpoint inhibitor (ICI)-based therapy for advanced hepatocellular carcinoma (HCC) remains a challenge as no available second-line treatment options have been studied in immunotherapy-pretreated patients. Particularly, the role of ICI rechallenge in patients with HCC is unclear, as data from prospective trials are lacking. We investigated the efficacy and safety of ICI-based regimens in patients with HCC pretreated with immunotherapy in a retrospective, international, multicenter study. Our data provide the rationale for prospective trials investigating the role of ICI-based regimens in patients who have progressed on first-line immunotherapy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
LGX完成签到,获得积分10
1秒前
1秒前
PeizeWu完成签到,获得积分10
1秒前
李五可完成签到,获得积分10
1秒前
11完成签到,获得积分10
1秒前
慕青的应助被小小酥采纳,获得10
1秒前
伊莎芳子完成签到,获得积分20
2秒前
心情不错关注了科研通微信公众号
2秒前
2秒前
zgx发布了新的文献求助10
2秒前
donk完成签到,获得积分10
2秒前
3秒前
3秒前
3秒前
充电宝的应助被何易采纳,获得10
3秒前
余香的应助被影墨采纳,获得10
3秒前
3秒前
jc发布了新的文献求助10
4秒前
披着羊皮的狼的应助被星耀采纳,获得10
4秒前
4秒前
嘻嘻完成签到,获得积分10
4秒前
华仔的应助被NingCp采纳,获得10
5秒前
LGX发布了新的文献求助10
5秒前
威武的QQ完成签到,获得积分10
5秒前
czyh完成签到,获得积分10
5秒前
willyt完成签到,获得积分10
5秒前
Tomma完成签到,获得积分10
6秒前
李亚楠发布了新的文献求助10
6秒前
35发布了新的文献求助10
6秒前
6秒前
FanLab发布了新的文献求助10
6秒前
7秒前
bkagyin的应助被yuan采纳,获得10
7秒前
无花果的应助被俭朴钢铁侠采纳,获得10
7秒前
DagenLiu完成签到,获得积分10
7秒前
s180500428完成签到,获得积分10
7秒前
小余完成签到,获得积分20
7秒前
贺茂思弦完成签到,获得积分10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181014
求助须知:如何正确求助?哪些是违规求助? 9571039
关于积分的说明 21816042
捐赠科研通 7777369
什么是DOI,文献DOI怎么找? 3433378
关于科研通互助平台的介绍 2557621
邀请新用户注册赠送积分活动 2479385